Strategic Upgrade: From Basic Generic Drugs to High-barrier Pharmaceutical Market
Release time:
2021-11-12
We concentrated resources on researching and promoting medicines targeting difficult and severe illnesses such as cardiovascular disorders, viral infections and tumors, which own high technical thresholds and market added value.
The year 2018 was a landmark turning point in the development journey of Baotai Pharmaceutical. After years of steady accumulation in basic pharmaceutical trade, the management team made a forward-looking strategic decision to complete comprehensive business transformation. The company gradually withdrew from the fiercely competitive low-end generic drug market, and shifted business focus to high-standard markets that implement strict GMP management norms.
We concentrated resources on researching and promoting medicines targeting difficult and severe illnesses such as cardiovascular disorders, viral infections and tumors, which own high technical thresholds and market added value. This profound transformation brought fundamental changes to our business mode. We no longer merely export finished pharmaceutical products, but extend business to technical guidance, production standard optimization and industrial capacity cooperation. The comprehensive upgrade greatly enhances our core competitiveness, brand influence and market bargaining power in the international pharmaceutical trade arena.
TAG:
Next:
Contact Us
Domestic Business：
Pharmaceuticals：
Medical Devices：
Send E-mail
Phone/Whatsapp
+86-15230180709 (Pharmaceuticals)
+86-18603110901 (Medical Devices)
Address
Linping District, Hangzhou City, Zhejiang Province, China
WHO WE ARE
Baotai (Hangzhou) Pharmaceutical Co., Ltd. is a comprehensive multinational pharmaceutical and healthcare enterprise with nearly 20 years of industry heritage.
